Company updateMoneycontrol
Motilal Oswal sets ALKEM target at Rs 5890
Neutral0
GreyOak summary
Motilal Oswal maintained its rating on ALKEM Laboratories, citing marginally better-than-expected revenue and EBITDA in Q2FY27.
What it affects
- Alkem LaboratoriesALKEMNeutral 0
Revenue and EBITDA beat estimates marginally.Rolling sentiment Negative -50
Source
Read the original at MoneycontrolMore Alkem Laboratories news
- Alkem shares fall 3% after Q2 results; MOFSL retains Neutral ratingBusiness Standard · Results ·
- Alkem shares decline 2% as HSBC maintains Hold ratingMoneycontrol · Company update ·
- Alkem PAT down at ₹675 crore; biotech sales down 37%BusinessLine · Results ·
- Alkem Lab Q2 profit falls 14.4% to Rs 667 crBusiness Standard · Results ·
- Alkem Labs Q2 revenue rises 14%, profit fallsCNBC-TV18 · Results ·